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Background: The diagnostic criteria of the metabolic syndrome (MS) have been applied in studies of obese adults to estimate
the metabolic risk-associated with obesity, even though no general consensus exists concerning its definition and clinical value.
We reviewed the current literature on the MS, focusing on those studies that used the MS diagnostic criteria to analyze children,
and we observed extreme heterogeneity for the sets of variables and cutoff values chosen.
Objectives: To discuss concerns regarding the use of the existing definition of the MS (as defined in adults) in children and
adolescents, analyzing the scientific evidence needed to detect a clustering of cardiovascular risk-factors. Finally, we propose a
new methodological approach for estimating metabolic risk-factor clustering in children and adolescents.
Results: Major concerns were the lack of information on the background derived from a child’s family and personal history; the
lack of consensus on insulin levels, lipid parameters, markers of inflammation or steato-hepatitis; the lack of an additive relevant
effect of the MS definition to obesity per se. We propose the adoption of 10 evidence-based items from which to quantify
metabolic risk-factor clustering, collected in a multilevel Metabolic Individual Risk-factor And CLustering Estimation (MIRACLE)
approach, and thus avoiding the use of the current MS term in children.
Conclusion: Pediatricians should consider a novel and specific approach to assessing children/adolescents and should not simply
derive or adapt definitions from adults. Evaluation of insulin and lipid levels should be included only when specific references for
the relation of age, gender, pubertal status and ethnic origin to health risk become available. This new approach could be useful
for improving the overall quality of patient evaluation and for optimizing the use of the limited resources available facing to the
obesity epidemic.
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Introduction
Since its inception in 1988,1 the diagnostic criteria of the
metabolic syndrome (MS) have been applied in several
studies in obese adults to estimate the metabolic risk
associated with obesity.2–4 The MS was first defined as a
combination of several metabolic risk-factors for cardio-
vascular disease (CVD) in one individual, including obesity,
insulin resistance, glucose intolerance, hypertension and a
characteristic dyslipidemia.5 No general consensus exists
concerning its definition, and in fact three definitions have
been proposed in adults, by the World Health Organization
(WHO),6 the European Group for the Study of Insulin
Resistance/International Diabetes Federation (EGIR/IDF)7–8
and the National Cholesterol Education Program, Adult
Treatment Panel III (ATP III).9 Moreover, recent seminal
papers10–14 pointed out several concerns about the definition
of the MS, among them that ‘too much critically important
information is missing to warrant its designation as a
syndrome’.12 Nonetheless, the three proposed definitions
have been used in several studies carried out in pediatric
populations, which reported high-prevalence of the MS in
obese children and adolescents.15–33 The results of these
studies varied according to the selected diagnostic criteria
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used, as established by a recent comparison study.34 More-
over, in an evaluation of the different prevalence yields using
different definition, Goodman et al.35 found that ATP III
definition identified half as many children and adolescents
as having MS as did WHO definition in the same population.
Thus, pediatricians are faced with the dilemma of whether
to use this simple diagnostic tool to identify among the
huge number of obese children those with high risk for
co-morbidity, despite the wide criticism it has received.12
The parameters of the MS develop in stages, according to
age-related changes in obesity, so the full syndrome cannot
generally be expressed at an early age.36 Moreover, it is
fundamental to take into account that in children and
adolescents, the pathophysiological basis and characteristics
of the MS are also influenced by growth and puberty,36,37
and not only by gender, ethnicity and body composition as
they are in adults. The available literature has focused on the
assessment of the MS in overweight and obese children;
however, we suspect that a clustering of risk-factors can also
be observed in normal-weight children and adolescents,18,22
as already shown in adults.38–40 Therefore, the adoption of
the current definitions of the MS, which have been
developed for obese adults, should be taken with extreme
caution in children and adolescents, as questioned clearly in
very recent reports.41,42
The aims of this review are to discuss the main concerns
regarding the use of the existing definition of the MS in
children and adolescents, in addition to analyzing the
scientific evidence needed to detect a clustering of cardio-
vascular risk-factors. Finally, we propose a new methodolo-
gical approach for estimating metabolic risk-factor clustering
in children and adolescents.
Actual features
We reviewed the relevant literature, focusing on those
studies that defined and/or used the MS diagnostic criteria
in children and adolescents. In Table 1 we present 15
papers,15–29 all of which used different sets of variables,
number of criteria and cutoff points to define the risk-factors
associated with the MS.43–60 The main differences concern
the techniques used to estimate adiposity (body mass index
(BMI) and/or waist circumference (WC)), and the variable(s)
chosen to evaluate glucose metabolism (fasting glucose,
Table 1 Published pediatric papers concerning the metabolic syndrome
# Authors Subjects’ age (years) Variables and cutoffs N of criteria
BMI WC BP Trigly HDL Ins Glu Others
1 Chen et al., 199915 5–17 75th 75th 25th 75th PI 75th X4
2 Csabi et al., 200016 1372 95th * * 95th TC* X4
3 Moreno et al., 200217 1172 75th 75th 25th 75th 75th UA 75th X4
4 Cook et al., 200318 12–19 90th 90th 90th* 10th* ** X3
5 de Ferranti et al., 200419 12–19 75th 90th * * ** X3
6 Goodman et al., 200420 1572 * * * * * X3
7 Lambert et al., 200421 9, 13, 16 85th 75th 75th 25th 75th * X3
8 Weiss et al., 200422 4–20 97th 95th 95th** 5th** GT*** X3
9 Cruz et al., 200423 8–13 90th 90th 90th* 10th* GT** X3
10 Duncan et al., 200424 12–19 90th 90th 90th* 10th* ** X3
11 Rodriguez-Moran et al., 200425 10–18 90th 90th 90th* 10th* ** *** X3
12 Boney et al., 200526 6, 7, 9, 11* 85th 95th 95th** 5th** GT*** X2
13 Viner et al., 200527 2–18 95th 95th 90th 10th * ** TC, GT*** X3
14 Janssen et al., 200528 5–18 80th 80th 20th 80th X3
15 Invitti et al., 200629 6–16 97th 97th 95th 95th 5th * GT,DM2, H** X3
Abbreviations: BMI, body mass index (weight/height2); BP, blood pressure (high BP, systolic and/or diastolic whenever not indicated); DM2, diabetes mellitus type
2; GT, glucose tolerance; Glu, fasting blood glucose; HDL, high-density lipoprotein-cholesterol; Ins, insulin; H, HOMA-IR; PI, Ponderal index (weight/height3); TC,
total cholesterol; Trigly, triglycerides; UA, uric acid; WC, waist circumference.
#1 cutoffs: 4th quartile of study population; triglycerides and HDL cholesterol used as a single item. #2 BP: mean arterial pressure (Ref. Soergel et al.43); *all lipids
(Ref. Romics et al.44); insulin X95th of 100 control children. #3 cutoffs: 4th quartile of study population. #4 WC: 90th of study population; BP: (Ref.45); *all lipids
(Ref. National Cholesterol Education Panel46); **(Ref.American Diabetes Association guideline47). #5 WC: 75th(Ref.Zhu et al.48), BP: 90th (Ref.45); *all lipids (Ref.The
lipid Research Clinics Program Epidemiology Committee49); ** X6.1 mmol/l. #6 ATP III criteria for all variables (Ref.Expert Panel on Detection9). #7 all variables
cutoffs derived from the study population; BP: only systolic; * X6.1 mmol/l. #8 BP: (Ref.45); *BMI: (Ref.Kuczmarski et al.50); **all lipids (Ref.NGHS Coordinating
Center51); ***glucose at 2-hour 140–200 mg/dl. #9 WC: (Ref.Fernandez et al.52); BP: (Ref.45); *all lipids (Ref.Hickman et al.53); **glucose at 2-hour 140–200 mg/dl.
#10 WC: 90th of study population; BP: (Ref.45); *all lipids (Ref.National Clolesterol Education Panel46); **(Ref.American Diabetes Association guideline47). #11 BP:
(Ref.45); * all lipids (Ref.National Clolesterol Education Panel46); **(Ref.Bloomgarden54); ***family history of obesity, DM2, hypertension, presence of low or high
birth weight. #12 *longitudinal study; BMI: (Ref.Centers of Disease Control and Prevention55); BP: (Ref.Task Force on Blood Pressure Control in Children56); **all
lipids (Ref.American Academy of Pediatrics National Cholesterol Education Program57), triglycerides and HDL cholesterol used as a single item; *** glucose at 2-hour
140–200 mg/dl. #13 BMI: (Ref.Cole et al.58); BP: only systolic (Ref.Task Force on Blood Pressure Control in Children56); all lipids (Ref.Hickman et al.53); *fasting insulin
(Ref.Goran et al.59); **X6.1 mmol/l. ***GT: glucose at 2-hour 140–200 mg/dl; fasting glucose, fasting insulin and impaired glucose tolerance used as a single item.
#14 cutoffs: 5 th quintile of study population. #15 cutoffs derived from control population; * (Ref.World Health Organization Department of Noncommunicable
Disease Surveillance60); **GT: (Ref.World Health Organization Department of Noncommunicable Disease Surveillance60).
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fasting insulin, homeostasis model assessment for insulin
resistance (HOMA-IR) or glucose tolerance to oral glucose
load). Blood pressure, triglycerides and high-density lipo-
protein (HDL) cholesterol were the more stable parameters,
but the criteria chosen to identify hypertension varied (only
systolic, systolic/diastolic or mean arterial pressure), and the
cutoff points for triglycerides and HDL cholesterol were
different. It is interesting to note that Cook et al.18 and De
Ferranti et al.19 evaluated the same population, National
Health and Nutrition Examination Survey III, using slightly
different criteria and obtained different prevalence. This
would also translate into different risk assessments.
Critical points
The main concern for pediatricians is that none of the
existing definitions of the MS is considered to be ideal.
Table 2 outlines the major and minor concerns for the
adoption of the adult MS diagnostic criteria in children and
adolescents, mainly based on the supposed (or known)
differences between obese children and obese adults.
Major concerns
The first major concern is related to the lack of an additive
relevant effect of the MS to the risk of obesity. To verify how
and which risk-factors are able to drive obesity to overt co-
morbidity, at least one (or more) long-term longitudinal
study is needed, starting at a very early age and continuing
until middle-aged or even elderly adults. This survey should
be conducted on a large cohort of subjects, of both genders
and different races, with a standardized variety of informa-
tion (including family history, birth data, lifestyle informa-
tion and body composition assessment over time, in
addition to measurement of hormonal and metabolic
parameters). Such a long-term study is useful in adults, but
is mandatory in children for whom the clinical evidence of
obesity-related morbidities often implies a long-term follow-
up. Looking at the current pediatric literature on the MS, it is
difficult to find long-term epidemiological studies that have
all the required information, and the maximum duration of
follow-up is not long enough.61,62
Only Rodriguez-Moran and co-workers25 looked at the
genetic background derived from the children’s family
history (i.e., phenotype and genotype). Knowledge of the
presence of obesity-related diseases in the family is as
important for the estimation of cardiovascular risk as the
evidence of metabolic abnormalities.42 It is difficult for a
pediatrician to comprehend how similar risk estimation can
be made for obese children coming from families with or
without cases of diabetes mellitus type 2 (DM2), dyslipide-
mia, hypertension or early-onset CVD. This information is
fundamental, as well as the presence of maternal obesity
and/or gestational diabetes, which have been shown to
increase the risk of obesity persistence and co-morbidity later
in life.26 Furthermore, the pediatrician does not under-
estimate the additional metabolic risk owing to a subject’s
birth-weight status (i.e., small for gestation age in particu-
lar).63–65
The main difference among current adult definitions of
the MS is in relation to insulin resistance evaluation. There is
a general consensus on the importance of insulin resistance
in the MS, but the ATP III and EGIR/IDF definitions estimate
glucose metabolism only by means of fasting serum glucose,
whereas the WHO criteria recognize any measure irrespective
of insulin resistance.6–9 Studies on glucose metabolism in
children and adolescents have shown that fasting hyper-
insulinemia may be a precursor of impaired glucose
tolerance and DM2, and that the detection of impaired
fasting glucose might be linked to DM2 onset.66–68 There-
fore, a pediatrician should avoid using a marker like
impaired fasting glucose, which is probably a late indicator
of glucose homeostasis derangement, preferring the use of
Table 2 Major and minor concerns for the adoption of the adult metabolic syndrome definition in children and adolescents
Major Minor
Not enough evidence from longitudinal studies on the additional health risk of
MS to obesity
Not enough information on tracking and long-term risk from childhood into
adulthood
No information on family and individual history No inclusion of ‘low-grade inflammation’ markers
No inclusion of fasting insulin level as an early marker of glucose homeostasis /
metabolism disturbances
No information on non-alcoholic fatty liver disease
No estimation of adipose tissue related hormones/biomarkers No information on environmental risk factors
No estimation of pubertal status
No available age-, gender- or race-specific reference values for all
characteristics
Low sensitivity and specificity of obesity criteria (BMI and/or WC) in obese
subjects
Equivalent value given to different items
No evidence on the cumulative health-related risk associated with the number
of criteria
No specific treatment for the MS
DM2 considered a risk-factor instead of an established disease
Abbreviations: BMI, body mass index; DM2, diabetes mellitus type 2; MS, metabolic syndrome; WC, waist circumference.
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fasting insulin level as an early detector of a long-term
risk-factor.
No other hormone levels or emerging biomarkers (e.g.
leptin, adiponectin, ghrelin, other adipokines, free fatty
acids or apolipoproteins) are included in any diagnostic
criteria of the MS, even though they have been proposed as
tools that provide valuable complementary information to
that obtained from traditional biomarkers.30,69,70 This is a
concern which is also true for adults, and not just for obese
children.
Pediatricians might find it surprising that classifications of
the MS exclude data on the subject’s puberty status and
timing, despite this being known to influence markedly
adipose tissue deposition, lipids and glucose metabolism
homeostasis.66,71,72 A metabolic derangement occurring
during puberty could have a deep impact on health risk for
obese subjects.66 The possibility of using a definition based
on insulin levels implies the availability of age/gender/race/
pubertal status-specific reference values. However, such
insulin references are in fact lacking, and need to be derived
from a large pediatric consensus.59,69
Published papers concerning the MS in children and
adolescents reported a high prevalence, ranging up to 50%
of the obese patients studied.18,19,22,24,27,29 This figure is
definitely alarming, but we know that the prevalence
recorded strongly depends on the definition chosen, with
the estimate being much higher if insulin is part of the
definition.34 Regardless of insulin, a low-discrimination
power parameter is the presence of obesity itself in the
definition, either directly via BMI or indirectly via WC. It is
easy to understand that, when BMI is used as part of the
diagnosis, screening for the MS in obese children could show
high prevalence; however, even when WC replaces BMI,
prevalence remains high, owing to the use of a WC cutoff
value (75–90th percentile) that includes the great majority of
obese children.28 All these considerations affect the sensiti-
vity and specificity of the diagnosis of the MS in obese
children, and could result in false-positive diagnoses.12 The
need for a re-evaluation of the MS diagnostic criteria is
also confirmed from the recent findings of Li et al.,73 who
diagnosed the MS in approximately 16% of normal-weight
children; previous studies have also found MS and/or insulin
resistance in healthy normal weight adults.38–40,74
According to the WHO definition,6 DM2 is included in the
diagnostic criteria for the MS. From a preventive point of
view, it is difficult for pediatricians to agree that the presence
of an overt disease like DM2 could have a clinical value
equivalent to HDL cholesterol reduction, as this definition
argues. Different items of MS diagnosis and risk assessment
probably have different importance in terms of outcome
prediction.12,42 Therefore, it is not clear which three
components are used to make the diagnosis and whether
the combination of any three is equally predictive. At the
same time, it is not clear which could be the management of
a child with only two items and therefore without a MS
diagnosis. Even a child with one item deriving from a family
with strong history of CVD or severe hypertension could
have a high-risk estimation.12,42 We strongly support the
view that maximal preventive and therapeutic efforts will
have to be used until individual future risk can be accurately
achieved. If we want to estimate risk at the population level
rather than at an individual level, it is necessary to use
continuous rather than dichotomous variables.10
Minor concerns
The available data did not show a marked tracking of the MS
for CVD risks either on short- and on long-term period11,72,75
and the predicting value of MS clustering seems not higher
than any single parameter.76
A consistent body of data about the pathogenetic role of
systemic indices of ‘low-grade inflammation’ in co-morbid-
ity is now available.12,13,22,77–80 However, at the present
time, they were not considered for the MS diagnosis.
Emerging data on elevated C-reactive protein in obese
children22,81 suggest it is an early candidate index, but
efforts should be pursued to fill the pathophysiological gap
uncovered by insulin resistance in the evolution of MS.
Moreover, the existence of an inflammatory process in
childhood obesity has been recently confirmed.82 In addi-
tion, a chronic liver damage, such as non-alcoholic steato-
hepatitis (NASH), could be taken into account for a complete
individual risk estimation, based on the high NASH
frequency in the pediatric obese population and on possible
multiple interrelationships between NASH and MS risk
factors.83,84
Lifestyle and environmental variables seem to correlate
with risk of developing the MS (for example, passive and
active tobacco smoke exposure, physical inactivity and
alcohol consumption), and could potentially be investigated
when a risk assessment for the MS has to be carried out in a
child.85,86
Metabolic risk-factor clustering estimation
Medical science usually defines a syndrome as an ‘aggregate
of symptoms and signs associated with any morbid process,
and constituting together the picture of the disease’.12,87 The
specific signs and symptoms are usually caused by a unifying
underlying pathology, and their combination confers a risk
that is different from the sum of the parts. It is necessary
to consider the term itself, the clear pathophysiology, the
variables included and excluded, the values needed for
making the diagnosis, and the different treatment possibi-
lities.12 Consequently, very recent reports discussed the
possibility of discouraging the growing use of the term
‘metabolic syndrome’, in favor of considering and subse-
quently treating each component separately.9,11,13,14 Several
authors have tried to give different names to the MS, adding
components to improve the validity of the overall diagno-
sis,13,14,16,36 but these may simply be causing confusion in
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daily clinical practice.13,14 In light of this background, and
taking into account the major and minor concerns discussed
above, we argue that pediatricians need to consider a novel
approach to assessing obese children, and should not
simply derive or adapt definitions from adults. Moreover,
the available definitions in children21,22 do not consider the
pathophysiological basis of the clustering of CVD risk-factors
of metabolic origin.21,34 Although, progress is being made in
understanding the complex gene–environment interaction
and associated developmental origin of risk-factors
clustering.88,89
Following the recent recommendation of Grundy14 re-
garding metabolic risk-factor clustering in adults, we propose
a new comprehensive approach for Metabolic Individual
Risk-factor And Clustering Estimation (MIRACLE) in chil-
dren and adolescents. Taking into account the pediatrician’s
role in preventing future diseases,90 we need first to direct
our efforts towards collecting data on all the plausible
variables to provide us with an overall picture, and then to
select those variables with solid evidence to substantiate
their relevance. In Figure 1, we outline a multilevel global
approach to examining patients. In brief, the overall
evaluation of the risk is based on the combination of a first
level that is anamnestic, a second level that is based on
the present evaluation, and a third level that is represented
by the possible clinical outcomes or diseases. We need to
investigate both the family and the individual’s history (i.e.
the past), to evaluate clinical and metabolic abnormalities
(i.e. the present) and then to identify clinical outcomes (i.e.
the future) that could appear if the clustering of the risk
factors continues for a long period of time, but could also
already be present.91–94 This three-level evaluation is not
considered as a ‘chronological’ evolution (i.e., step by step).
Table 3 outlines our proposed components of the MIRACLE
approach, together with suggested estimation methods and
possible risk criteria, based on the available literature.
Clearly, it is not simple to define and to quantify each item,
and some suggested risk criteria reference standards are still
missing, but this pathway could help pediatricians to decide
which subjects to evaluate and follow-up in depth. In this
scenario, we consider hypertension, recently confirmed a
frequent finding in childhood obesity,95–96 as a clinical
feature because of its possibility to be assessed during a
standard clinical examination.
In Table 4 we consider only those components for which
there is strong enough evidence for a clear definition. For
family history, we have included the presence of early CVD,
DM2 and hypertension. We have not included a family
history of obesity, because there is no general agreement as
to whether this factor adds an independent risk for CVD in
addition to the presence of obesity in the subject. Family
dyslipoproteinemia was not considered because obesity-
related dyslipidemia (i.e., high triglycerides and low HDL-
cholesterol levels) is not usually assessed by the general
practitioner and because dyslipoproteinemia is a risk-factor
and not a clinical outcome or a disease (unlike CVD, DM2
or hypertension). Family and individual lifestyle as well as
infant feeding can be assessed, but there are no defined
criteria to characterize unhealthy patterns. Socioeconomic
status can also be assessed using different indicators and the
most widely accepted is parental education level. However,
the relationship between paternal education and CVD risk
factors has not been adequately established, and there is
also a potential risk of stigmatizing the family and the child.
Adiposity rebound plays a major role in the development
of obesity, but it remains to be clarified whether it has an
independent role in the development of CVD. We did not
include individual obesity history because it is difficult to
estimate the exact date of appearance and therefore the
duration of obesity. The presence of striae, common in
adolescent obesity, is also difficult to assess objectively.
There is no consensus on age-, gender- and ethnic-group-
specific cutoffs for WC related to morbidity in children, but
some standard references are now available in different
populations.52,102–105 Figure 2 compares the 90th WC centile
in boys (Figure 2a) and girls (Figure 2b), and shows a
difference between children from the US (i.e., European-
American), UK, Spain, Canada and Australia. This difference
is mainly related to the higher prevalence of obesity in North
American than in European children.106 Other factors, such
as measurement procedures, year of data collection and
sample size, could also affect the prevalence. As WC is an
accurate estimate of abdominal adiposity,107 and the avail-
able European standard references do not adequately detect
its excess, we propose the use of the US 90th percentile to
increase sensitivity. Some recent papers suggested that WC is
an independent predictor of insulin resistance and CVD risk
factors.28,108,109 However, we strongly recommend carrying
out more research to define the optimal WC values to detect
an excess of abdominal adiposity in children.
Among the items that we do not consider in Table 4,
insulin and lipid exclusion need justification. We acknowl-
edge that insulin resistance is a key factor associated with
long-term obesity-related co-morbidities.66 However, the
Multi-level approach to the overall Metabolic Individual Risk-factor



















Figure 1 Comprehensive framework of the metabolic individual risk-factor
and clustering estimation.
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euglycemic hyperinsulinemic clamp, the golden standard for
insulin resistance detection, cannot be used in pediatric
clinical settings. Elevated fasting plasma insulin levels are
considered a surrogate of insulin resistance but, at the
present time, there are neither standardized assays available
nor age-, maturation-, gender- and ethnic-specific reference
values. The same could be applied for triglycerides and
HDL-cholesterol serum levels. Moreover, the cutoff points
used to identify abnormal lipid profiles have limited ability
to predict children or adolescents who will have high-risk
lipoprotein levels as adults.53,57 Recently, abnormal lipid
thresholds have become available for 12–19-year-old adoles-
cents110 as indirectly linked to health risk, but they need to
be validated with longitudinal studies. In addition, even
low-density lipoprotein (LDL) cholesterol, which was re-
cently related to cardiovascular risk-factors and showed long-
term tracking power, should be included as parameter to
measure.42,111,112 When new research fills these knowledge
gaps, insulin and lipid-profile parameters, which we believe
are both potential factors to consider, could be included as
components for evaluation.
Returning to evidence-based items and looking at clinical
management of such a list (Table 4), we can determine the
presence or the absence of each factor in the individual. One
could argue that a global score could help to define better the
subject’s risk, and propose to assign a value of 1 to ‘presence’,
and a value of 0 to ‘absence’. Moreover, a separation of the
family and individual history score from the clinical and
metabolic score is possible, to distinguish potential factors
from the already expressed ones. If a score was to be created,
it could consider the 10 evidence-based items that quantify
MIRACLE. Having at least half of these items ‘positive’ (or
Table 3 MIRACLE characteristics in pediatric clinical practice, according to the levels shown in Figure
Characteristic Estimation method Suggested risk criteria
Family history
Obesity Parental weight and height measured At least one parent with BMI 430 kg/m2
Early cardiovascular disease Parents and grandparents history At least one relative with cardiovascular disease o55 years (man)
or o65 years (woman)
DM2 Parents and grandparents history At least one relative with DM2
Dyslipoproteinemia Parents and grandparents history At least one relative with any confirmed lipid abnormality
Hypertension Parents and grandparents history At least one relative affected
Lifestyle Family dietary and physical activity history At least one relative with low fruit and vegetable, high sugar and
fat consumption and/or sedentary
Socioeconomic status Parental education level Low education level
Individual history
Birth weight Verified birth weight related to GA Small and large for GA birth weight
Infant feeding Breast feeding duration and age of solid food introduction No or short duration breast feeding
Adiposity rebound Longitudinal record of pediatric BMI reference curves Early adiposity rebound
Obesity history Longitudinal record of pediatric BMI reference curves Obesity duration
Age of menarche Personal history o12 years of age
Ethnic origin Parental interview Indo-Asians, Hispanics, African-Americans
Lifestyle Personal dietary and physical activity history Low fruit and vegetable, high sugar and fat consumption and/or
sedentary
Clinical features
Body composition Weight, height and WC measurements BMI corresponding to adult value of 430 kg/m2, age and gender-
specific
Blood pressure Systolic and diastolic blood pressure appropriately measured Systolic or diastolic blood pressure 495th percentile for age,
gender and height
Acanthosis nigricans Clinical examination At least one lesion
Striae distensae Clinical examination At least one body location
Metabolic abnormalities
Insulin resistance Fasting plasma insulin levels
IGT Oral glucose tolerance test Fasting glucose 100–126 mg/dl or glucose at 120 min. 140–
200 mg/dl
DM2 Oral glucose tolerance test Fasting glucose 4126 mg/dl or glucose levels at 120 min.
4200 mg/dl
Dyslipoproteinemia Triglycerides and HDL-C serum levels
Other potential factors
Inflammation CRP serum levels, other markers
Adipokines Adiponectin and other markers
NAFLD Liver echotomography and enzymes
Abbreviations: BMI, body mass index; CRP, C-reactive protein, DM2, diabetes mellitus type 2; GA, gestational age; HDL-C, high density lipoprotein cholesterol; IGT,
impaired glucose tolerance; MIRACLE, metabolic individual risk factor and clustering estimation; NAFLD, Non-alcoholic fatty liver disease; WC, waist circumference.
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present) could mean that the subject needs very careful
follow-up and evaluation over time. However, we strongly
discourage calculating a score, because the identical value
given to any item does not represent its real weight on CVD
risk development. In addition, no published data could
support different strategies based on the score. Nevertheless,
this approach drives the pediatrician to an overall evaluation
of the subject, by giving a fundamental value to anamnesis
and physical examination. For future steps, it is fundamental
to test the usefulness of such criteria to assess long-term
cardiovascular outcomes or diseases in large longitudinal
surveys.
Conclusion
In this paper, we carefully analyzed, in a clinical manner, the
different criteria used in available pediatric studies to
diagnose the MS. The great majority of pediatricians adopted
criteria proposed for adults, and there were no reliable
definitions of the MS in children. We presented our major
and minor concerns regarding the use of existing definitions
of the MS in children and adolescents. We also discussed the
importance of considering factors derived from family and
individual history, as well as from physical examination, in
addition to metabolic risk-factor clustering. Finally, we
proposed new potential items that should be considered in
children and adolescents. The main outcome of this exercise
has been 10 evidence-based items from which we could
quantify the MIRACLE (see Table 4). We are aware that this is
Table 4 MIRACLE of those items for which there is strong enough evidence for a clear definition
Items Definition or risk criteria Reference
Family history
Early cardiovascular diseases One relative with cardiovascular disease o55 years (man) or
o65 years (woman)
Kavey et al.97
DM2 One first-degree relative affected Speise et al.98
Hypertension One first-degree relative affected National High Blood Pressure Education Program Working
Group on High Blood Pressure in Children and Adolescents99
Individual history
Small for gestational age Birth weight for length o10th percentile for gender and
gestational age
Boney et al.26
Ethnic origin Indo-Asians, Hispanics; African-Americans Speise et al.98
Clinical features
BMI BMI corresponding to adult value of 430 kg/m2 Cole et al.100
Waist circumference 490th percentile age, gender, ethnic-specific Fernandez et al.52
Hypertension Systolic or diastolic BP 495th percentile age, gender and
height-specific
National High Blood Pressure Education Program Working
Group on High Blood Pressure in Children and Adolescents99
Acanthosis nigricans One lesion Kobaissi et al.101
Metabolic abnormalities
IGT or DM2 IGT: fasting glucose 100–126 mg/dl or glucose at 120 min.
140–200 mg/dl; DM2: fasting glucose 4126 mg/dl or glucose
at 120 min. 4200 mg/dl
World Health Organization Department of Noncommunicable
Disease Surveillance60
Total risk estimation


















2 4 6 8 10 12 14 16 18
















Figure 2 WC 90th centile (in cm) in US (European-American),52 UK,102
Spain,103 Australia 104 and Canada 105 boys (a) and girls (b) according to age.
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just a step towards developing final estimation criteria;
however, we hypothesize that this new approach would
improve the overall quality of evaluation in children, it
could optimize the use of the limited resources available to
combat the obesity epidemic, and ultimately it may help to
classify the risk of developing CVD in obese subjects. The
pediatrician periodically needs to re-evaluate the growing
subject, as the overall risk estimation could rapidly change.
In addition, both normal-weight and overweight children
and adolescents could be checked using this approach, as
metabolic risk-factor clustering is not only peculiar in obese
subjects. This complex approach to the subject requires time
availability and more specific attention, but in the long-term
these qualities could play a major role in health perspectives
of the subject.
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